Cargando…

PI3K mutations in breast cancer: prognostic and therapeutic implications

The PI3K pathway is the most frequently enhanced oncogenic pathway in breast cancer. Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (∼30%) observed, along with protein loss of PTEN. Since the first discovery of PIK3CA mutations in solid malignancies in 2004, numerous stud...

Descripción completa

Detalles Bibliográficos
Autor principal:	Mukohara, Toru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440424/ https://www.ncbi.nlm.nih.gov/pubmed/26028978 http://dx.doi.org/10.2147/BCTT.S60696

Ejemplares similares

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
por: Xiao, Weikai, et al.
Publicado: (2021)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
por: Massacesi, Cristian, et al.
Publicado: (2016)

Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
por: Mukohara, Toru
Publicado: (2011)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Perspective: Potential Impact and Therapeutic Implications of Oncogenic PI3K Activation on Chromosomal Instability
por: Vanhaesebroeck, Bart, et al.
Publicado: (2019)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

Efficacy of PI3K inhibitors in advanced breast cancer
por: Verret, B, et al.
Publicado: (2019)

Clinical implications of Girdin and PI3K protein expression in breast cancer
por: JIN, FENG, et al.
Publicado: (2013)

PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics
por: Ghoneum, Alia, et al.
Publicado: (2019)

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
por: Fujimoto, Yumi, et al.
Publicado: (2020)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
por: Josephs, Debra H., et al.
Publicado: (2016)

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition
por: Conciatori, Fabiana, et al.
Publicado: (2022)

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
por: Miller, Todd W, et al.
Publicado: (2011)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Elevated PI3K signaling drives multiple Breast Cancer subtypes
por: Adams, Jessica R., et al.
Publicado: (2011)

Overview of the relevance of PI3K pathway in HR-positive breast cancer
por: Vasan, N, et al.
Publicado: (2019)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications
por: Aguayo, Francisco, et al.
Publicado: (2023)

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
por: Davis, Nicole M., et al.
Publicado: (2014)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
por: Bertucci, Alexandre, et al.
Publicado: (2023)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
por: Cheaib, Bianca, et al.
Publicado: (2015)

Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer
por: Khatpe, Aditi S., et al.
Publicado: (2021)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

The PTEN–PI3K Axis in Cancer
por: Papa, Antonella, et al.
Publicado: (2019)

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
por: Churi, Chaitanya R., et al.
Publicado: (2014)

Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL
por: Guarente, Valerio, et al.
Publicado: (2021)

BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies
por: Wang, Pei-Pei, et al.
Publicado: (2022)

PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds
por: Yuan, Yeqin, et al.
Publicado: (2023)

PI3K and AKT: Unfaithful Partners in Cancer
por: Faes, Seraina, et al.
Publicado: (2015)

Drugging PI3K in cancer: refining targets and therapeutic strategies
por: Yap, Timothy A, et al.
Publicado: (2015)

Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer
por: Potter, C P S, et al.
Publicado: (2003)

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer
por: Korkola, James E., et al.
Publicado: (2015)

BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
por: Nakayama, Izuma, et al.
Publicado: (2020)

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
por: Nur Husna, Siti Muhamad, et al.
Publicado: (2018)

PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
por: Fuso, Paola, et al.
Publicado: (2022)

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer
por: Lopes, Gabriel Lima, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_orbik7b3f5qhq6at29cilckldr